Illumina, Inc. (NASDAQ:ILMN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
Illumina, Inc. (NASDAQ:ILMN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.02(d)
On February 18, 2017, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from ten to 11 members and elected John Thompson to serve on the Board beginning May 3, 2017. Mr. Thompson has been assigned to serve in the class of directors standing for election at the Company’s 2018 annual meeting of stockholders, which currently includes Blaine Bowman, Karin Eastham, and Jay Flatley, and consistent with the Company’s Corporate Governance Guidelines, Mr. Thompson will stand for election by the Company’s stockholders at the Company’s 2018 annual meeting of stockholders to serve for a three-year term commencing with such meeting. There is no arrangement or understanding between Mr. Thompson and any other person to which he was selected as a director. In addition, Mr. Thompson is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Mr. Thompson will participate in the non-employee director compensation programs described under “Director Compensation” in the Company’s proxy statement filed on April 8, 2016.
A copy of the press release announcing the appointment of Mr. Thompson is attached as Exhibit 99.1 to this Current Report on Form 8-K.
About Illumina, Inc. (NASDAQ:ILMN)
Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets. Illumina, Inc. (NASDAQ:ILMN) Recent Trading Information
Illumina, Inc. (NASDAQ:ILMN) closed its last trading session down -2.26 at 161.10 with 892,449 shares trading hands.
Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets. Illumina, Inc. (NASDAQ:ILMN) Recent Trading Information
Illumina, Inc. (NASDAQ:ILMN) closed its last trading session down -2.26 at 161.10 with 892,449 shares trading hands.